Hikma Pharmaceuticals (GB:HIK) has released an update.
Hikma Pharmaceuticals has announced a robust first half for 2024 with a 10% increase in group revenue and strong performance across all business segments. The company highlights significant growth in its Branded and Generics businesses, as well as strategic acquisitions, such as parts of Xellia Pharmaceuticals, which is expected to bolster its Injectables business. With this momentum, Hikma has raised its full-year revenue and profit guidance, as it continues to expand its global presence.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.